Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Ryder (R)
Consensus Price Target: $299.56 (25.8% implied return)
As one of the first companies to introduce the idea of leasing trucks, Ryder (NYSE: R) provides rental vehicles to businesses and delivers packages directly to homes or businesses.
Why Are We Hesitant About R?
- Annual sales growth of 2.4% over the last two years lagged behind its industrials peers as its large revenue base made it difficult to generate incremental demand
- Gross margin of 19.7% reflects its high production costs
- Cash-burning history makes us doubt the long-term viability of its business model
Ryder’s stock price of $238.19 implies a valuation ratio of 14.8x forward P/E. To fully understand why you should be careful with R, check out our full research report (it’s free).
Commercial Vehicle Group (CVGI)
Consensus Price Target: $7.50 (145% implied return)
Formed from a partnership between two distinct companies, CVG (NASDAQ: CVGI) offers various components used in vehicles and systems used in warehouses.
Why Are We Out on CVGI?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 5.8% annually over the last five years
- Earnings per share decreased by more than its revenue over the last five years, partly because it diluted shareholders
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
At $3.06 per share, Commercial Vehicle Group trades at 24.8x forward P/E. If you’re considering CVGI for your portfolio, see our FREE research report to learn more.
Phibro Animal Health (PAHC)
Consensus Price Target: $44 (24.6% implied return)
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Does PAHC Fall Short?
- Revenue base of $1.52 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Estimated sales growth of 3.6% for the next 12 months implies demand will slow from its two-year trend
- Poor free cash flow margin of 0.9% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
Phibro Animal Health is trading at $35.33 per share, or 10x forward P/E. Read our free research report to see why you should think twice about including PAHC in your portfolio.
Stocks We Like More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
